|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 43.87 EUR | +2.78% |
|
+5.18% | +18.43% |
| 01:08pm | Bayer AG - FDA grants orphan drug designation to cell therapy OPCT-001 | RE |
| 10:47am | DAVOS: Top Executive Fears Widening Economic Gap with the US | DP |
| Capitalization | 4.19TCr 4.9TCr 3.89TCr 3.65TCr 6.77TCr 4,49300Cr 7.25TCr 45TCr 18TCr 2,12300Cr 18TCr 18TCr 7,75600Cr | P/E ratio 2025 * |
182x | P/E ratio 2026 * | 16.7x |
|---|---|---|---|---|---|
| Enterprise value | 7.37TCr 8.62TCr 6.84TCr 6.42TCr 12TCr 7,89500Cr 13TCr 79TCr 31TCr 3,73200Cr 32TCr 32TCr 13,63000Cr | EV / Sales 2025 * |
1.61x | EV / Sales 2026 * | 1.54x |
| Free-Float |
100% | Yield 2025 * |
0.26% | Yield 2026 * | 1.26% |
Last Transcript: Bayer AG
| 1 day | +2.80% | ||
| 1 week | +5.18% | ||
| Current month | +18.43% | ||
| 1 month | +23.62% | ||
| 3 months | +60.23% | ||
| 6 months | +59.06% | ||
| Current year | +18.43% |
| 1 week | 41.27 |  | 44.98 |
| 1 month | 35.4 | | 44.98 |
| Current year | 36.88 | | 44.98 |
| 1 year | 18.38 | | 44.98 |
| 3 years | 18.38 | | 65.66 |
| 5 years | 18.38 | | 67.99 |
| 10 years | 18.38 | | 123.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
William Anderson
CEO | Chief Executive Officer | 59 | 01/06/2023 |
| Director of Finance/CFO | 56 | 01/06/2018 | |
Christian Rommel
CTO | Chief Tech/Sci/R&D Officer | 59 | 01/02/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Paul Achleitner
BRD | Director/Board Member | 69 | 01/04/2002 |
André van Broich
BRD | Director/Board Member | 55 | 01/04/2012 |
| Director/Board Member | 66 | 01/04/2022 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | -.--% | 4.28% | 962 M€ | |
| +1.02% | 4.1% | 1 M€ | |
| 0.00% | 4.1% | 1 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +2.78% | +5.18% | +104.43% | -21.68% | 4.9TCr | |
| +3.58% | +0.49% | +45.28% | +211.65% | 97TCr | |
| -0.09% | -0.25% | +47.15% | +29.20% | 53TCr | |
| +0.99% | -2.59% | +25.22% | +44.49% | 38TCr | |
| +0.62% | +0.78% | +28.35% | +17.38% | 37TCr | |
| +0.95% | -6.06% | +21.93% | +22.09% | 28TCr | |
| +0.24% | -1.28% | +28.22% | +34.12% | 28TCr | |
| +3.70% | +2.19% | -32.61% | -19.93% | 26TCr | |
| +1.52% | +0.09% | +15.45% | +1.06% | 28TCr | |
| +3.81% | +4.45% | +25.03% | +30.53% | 19TCr | |
| Average | +1.35% | -0.49% | +30.85% | +34.89% | 35.68TCr | |
| Weighted average by Cap. | +0.58% | -0.64% | +30.29% | +72.43% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 4.57TCr 5.35TCr 4.24TCr 3.98TCr 7.38TCr 4,89700Cr 7.91TCr 49TCr 19TCr 2,31500Cr 20TCr 20TCr 8,45500Cr | 4.6TCr 5.38TCr 4.27TCr 4TCr 7.43TCr 4,92600Cr 7.95TCr 49TCr 19TCr 2,32800Cr 20TCr 20TCr 8,50400Cr |
| Net income | 59Cr 69Cr 55Cr 51Cr 95Cr 6.33TCr 102.13Cr 629.09Cr 248.94Cr 2.99TCr 258.99Cr 253.7Cr 11TCr | 259.71Cr 303.75Cr 241.08Cr 226.1Cr 419.47Cr 28TCr 449.16Cr 2.77TCr 1.09TCr 13TCr 1.14TCr 1.12TCr 48TCr |
| Net Debt | 3.18TCr 3.71TCr 2.95TCr 2.77TCr 5.13TCr 3,40300Cr 5.49TCr 34TCr 13TCr 1,60800Cr 14TCr 14TCr 5,87500Cr | 2.88TCr 3.37TCr 2.67TCr 2.51TCr 4.65TCr 3,08300Cr 4.98TCr 31TCr 12TCr 1,45700Cr 13TCr 12TCr 5,32200Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 22/26/22 | 43.84 € | +2.71% | 8,82,261 |
| 21/26/21 | 42.68 € | -0.54% | 28,50,814 |
| 20/26/20 | 42.92 € | -3.34% | 43,33,938 |
| 19/26/19 | 44.40 € | +6.95% | 84,06,445 |
| 16/26/16 | 41.52 € | -1.38% | 33,76,608 |
Delayed Quote Xetra, January 22, 2026 at 04:04 pm IST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BAYN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition